NCT00705744

CompletedPhase 3

Dermacyd Femina (Lactic Acid) - Photo Dermatological Evaluat...

Sanofi Source

Compare

Other study identifiers

Sponsor study identifier

LACAC_L_03982

Study Type

interventional

Actual enrollment (reported)

26

Locations

1 country

Sites

1

Timeline

Study Start

April 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

May 2008

Actual (reported)

Study Completion

Not reported

Date not reported

Brief Summary

To prove the absence of photo irritation and photo sensitivity potential of the product Dermacyd Femina.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 26 participants
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
April 2008
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
May 2008
Actual (reported)
First Submitted
June 25, 2008
Actual (reported)
First Posted
June 26, 2008
Actual (reported)

Last Updated: April 15, 2009
Status Verified: April 2009
Last Update Submitted: April 14, 2009

Conditions

Hygiene

Outcome Measures

Primary Outcomes (2)

The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale
5 weeks
The sensibility will be evaluated according to the skin type.
5 weeks

Study Arms (1)

I

EXPERIMENTAL

Drug: Lactic acid (Dermacyd Femina)

Interventions

Lactic acid (Dermacyd Femina)Drug

I

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 60 Years

Sexfemale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Phototype Skin II and III;
Integral skin test in the region;

You may not qualify if:

Sponsors & Collaborators

Sanofi
Industrylead

Study Sites (1)

Sanofi-aventis

São Paulo, São Paulo, Brazil

MeSH Terms

Interventions

Lactic Acid

Intervention Hierarchy (Ancestors)

LactatesHydroxy AcidsCarboxylic AcidsOrganic Chemicals

Study Officials

Jaderson Lima, MD
Sanofi
STUDY DIRECTOR

Enrollment

26 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NA
Masking: NONE
Purpose: SUPPORTIVE CARE
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

June 25, 2008

First Posted

June 26, 2008

Study Start

April 2008

Date type not reported

This date has not been verified as actual or estimated.

NCT00783666

Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Photo Evaluation

Phase 3Completed

NCT00784056

Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Photo Evaluation

Phase 3Completed

NCT00933257

Dermacyd PH_DESILSTY_FR (Lactic Acid) - Photo Evaluation - Stay on Frutal

Phase 3Completed

NCT00784069

Dermacyd Breeze (Lactic Acid) Pocket BR - Photo Evaluation

Phase 3Completed

NCT00933842

Dermacyd PH_DESILSTY_FL (Lactic Acid) - Photo Evaluation - Stay on Floral

Phase 3Completed

NCT00785590

Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Photo Evaluation.

Phase 3Completed

Lactation or gestation;
Use of Anti-inflammatory and/or immuno-suppression drugs 15 days before the selection;
Diseases which can cause immunity decrease, such as HIV, diabetes;
Use of drug photosensitizer;
History of sensitivity or irritation for topic products;
Active cutaneous disease which can change the study results;
History or photodermatosis active;
Family or personal antecedent of cutaneous photoinduced neoplasias;
Presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and keratoses actinium;
Intense solar exposure in the study area;
Use of new drugs or cosmetics during the study;
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contact the study team to confirm eligibility.

Primary Completion

May 2008

Actual (reported)

Last Updated

April 15, 2009

Record last verified: 2009-04

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00705744
Data provider: ClinicalTrials.gov
Source updated: 2009-04-15
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:37:11 UTC

Locations

BR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (2)

Study Arms (1)

I

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations